Liang Xue-feng, Ma Dong-chu, Ding Zhen-yu, Liu Zhao-zhe, Guo Fang, Liu Liang, Yu Hui-ying, Han Ya-ling, Xie Xiao-dong
Cancer Diagnosis and Treatment Center of PLA, General Hospital of Shenyang Military Region, Shenyang 110840, China.
Email:
Zhonghua Zhong Liu Za Zhi. 2013 Oct;35(10):764-8.
To explore the effect of autologous cytokine-induced killer cells on the quality of life in patient with breast cancer who have already finished the adjuvant chemotherapy.
One hundred and twenty-eight postoperative patients with breast cancer who underwent anthracycline-based adjuvant chemotherapy were enrolled in this prospective study, and they were randomized into 2 groups, i.e., treatment group, which received the therapy of CIK cells transfusion, and control group, which was given regular follow-up. Meanwhile, patients with positive hormone receptor in the two groups were given endocrine therapy, and the patients with positive axillary lymph nodes were given radiotherapy to the chest wall and regional lymph nodes. The difference of quality of life between the two groups was analyzed according to the EORTC QLQ-BR53 quality of life questionnaire, and the adverse reactions were monitored.
As regarding the functional evaluation, the physical function scores of patients of the treatment group were (83.43 ± 14.87) and (88.55 ± 11.62) at 3 and 6 months after the CIK cell therapy, respectively, significantly higher than the baseline value [(74.83 ± 13.82), P < 0.05)]. Global health status/QOL scores were (83.30 ± 19.09) and (89.68 ± 10.81), significantly higher than the baseline value [(77.72 ± 21.05), P < 0.05]. As regarding symptoms, the scores of fatigue, nausea, vomiting and loss of appetite of patients in the treatment group were higher than the baseline value, with significant differences (P < 0.05). The nausea and vomiting scores in the control group at 3 and 6 months of followed-up were (26.67 ± 22.56) and (21.47 ± 21.06), significantly lower than the baseline values [(33.31 ± 27.07), P < 0.05]. The scores of worrying about the future in the patients of treatment group were (47.56 ± 30.84) and (42.33 ± 26.95) after 3 and 6 months, significantly better than the baseline value [(57.41 ± 30.63), P < 0.05]. The systematic therapy side effects scores were (31.95 ± 27.52) and (23.72 ± 22.87), significantly better than the baseline value [(40.56 ± 26.28), P < 0.05]. The scores of arm edema were (45.26 ± 25.42) and (36.61 ± 20.51), significantly milder than the baseline value [(55.11 ± 22.82), P < 0.05]. In the control group, the scores of arm edema were (44.85 ± 28.94) and (38.64 ± 23.68), significantly lower than the baseline values [(53.26 ± 23.84) points, P < 0.05]. Alopecia scores were (29.93 ± 24.72) and (24.18 ± 22.66), significantly lower than the baseline values [(35.92 ± 22.08), P < 0.05]. In the treatment group, the patients' physical function, social function and global health status/QOL, fatigue, insomnia, and worrying about the future rates were significantly higher than that of the control group (P < 0.05 for all). Three patients after CIK reinfusion had transient fever, and 6 cases felt pain in the lower limb, but the symptoms were relieved after symptomatic treatment.
Therapy of autologous CIK cells transfusion can significantly improve the quality of life of breast cancer patients, and the adverse reactions during the treatment can be alleviated by symptomatic treatment.
探讨自体细胞因子诱导的杀伤细胞对已完成辅助化疗的乳腺癌患者生活质量的影响。
128例接受蒽环类辅助化疗的乳腺癌术后患者纳入本前瞻性研究，随机分为2组，即接受CIK细胞输注治疗的治疗组和接受定期随访的对照组。同时，两组激素受体阳性患者给予内分泌治疗，腋窝淋巴结阳性患者给予胸壁及区域淋巴结放疗。根据欧洲癌症研究与治疗组织QLQ-BR53生活质量问卷分析两组生活质量差异，并监测不良反应。
在功能评估方面，治疗组患者CIK细胞治疗后3个月和6个月的身体功能评分分别为(83.43±14.87)和(88.55±11.62)，显著高于基线值[(74.83±13.82)，P<0.05]。总体健康状况/生活质量评分分别为(83.30±19.09)和(89.68±10.81)，显著高于基线值[(77.72±21.05)，P<0.05]。在症状方面，治疗组患者疲劳、恶心、呕吐和食欲减退的评分高于基线值，差异有统计学意义(P<0.05)。对照组随访3个月和6个月时的恶心和呕吐评分分别为(26.67±22.56)和(21.47±21.06)，显著低于基线值[(33.31±27.07)，P<0.05]。治疗组患者治疗后3个月和6个月对未来担忧的评分分别为(47.56±30.84)和(42.33±26.95)，显著优于基线值[(57.41±30.63)，P<0.05]。系统治疗副作用评分分别为(31.95±27.52)和(23.72±22.87)，显著优于基线值[(40.56±26.28)，P<0.05]。手臂水肿评分分别为(45.26±25.42)和(36.61±20.51)，显著轻于基线值[(55.11±22.82)，P<0.05]。对照组手臂水肿评分分别为(44.85±28.94)和(38.64±23.68)，显著低于基线值[(53.26±23.84)分，P<0.05]。脱发评分分别为(29.93±24.72)和(24.18±22.66)，显著低于基线值[(3
